MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Alcon Inc

Cerrado

SectorSanidad

89.7 -2.86

Resumen

Variación precio

24h

Actual

Mínimo

89.26

Máximo

92.53

Métricas clave

By Trading Economics

Ingresos

21M

284M

Ventas

48M

2.5B

P/B

Media del Sector

46.307

63.778

BPA

0.72

Rentabilidad por dividendo

0.28

Margen de beneficios

11.351

Empleados

25,599

EBITDA

56M

397M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+15.91% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.28%

2.39%

Próximas Ganancias

13 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

5.9B

47B

Apertura anterior

92.56

Cierre anterior

89.7

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

180 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Alcon Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 mar 2025, 21:22 UTC

Adquisiciones, fusiones, absorciones

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24 mar 2025, 12:36 UTC

Adquisiciones, fusiones, absorciones

Alcon to Buy Lensar in Deal Worth Up to $430 Million

12 nov 2024, 18:48 UTC

Ganancias
Principales Movimientos del Mercado

Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View

26 mar 2025, 21:55 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26 mar 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26 mar 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26 mar 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26 mar 2025, 20:31 UTC

Adquisiciones, fusiones, absorciones

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26 mar 2025, 20:31 UTC

Adquisiciones, fusiones, absorciones

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26 mar 2025, 20:31 UTC

Adquisiciones, fusiones, absorciones

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26 mar 2025, 20:30 UTC

Adquisiciones, fusiones, absorciones

Alcon Acquires Majority Interest in Aurion Biotech

24 mar 2025, 12:21 UTC

Adquisiciones, fusiones, absorciones

Alcon to Buy Lensar in Deal Worth Up to $430M

24 mar 2025, 12:05 UTC

Adquisiciones, fusiones, absorciones

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24 mar 2025, 12:05 UTC

Adquisiciones, fusiones, absorciones

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24 mar 2025, 12:04 UTC

Adquisiciones, fusiones, absorciones

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

24 mar 2025, 12:04 UTC

Adquisiciones, fusiones, absorciones

Alcon Will Purchase All Outstanding Shrs of LENSAR for $14.00 Per Shr in Cash >ALC

24 mar 2025, 12:03 UTC

Adquisiciones, fusiones, absorciones

Alcon: Acquisition Includes ALLY Robotic Cataract Laser Treatment System, LENSAR's Proprietary Streamline Software Technology and LENSAR Legacy Laser System >ALC

24 mar 2025, 12:03 UTC

Adquisiciones, fusiones, absorciones

Alcon Agrees to Acquire LENSAR >ALC

24 mar 2025, 12:00 UTC

Adquisiciones, fusiones, absorciones

Alcon Agrees To Acquire LENSAR, Inc. >ALC LNSR

25 feb 2025, 21:33 UTC

Ganancias

Alcon Sees 2025 Adj EPS $3.15-Adj EPS $3.25 >ALC.EB

25 feb 2025, 21:33 UTC

Ganancias

Alcon Sees 2025 Sales $10.2B-$10.4B >ALC.EB

25 feb 2025, 21:32 UTC

Ganancias

Alcon: Board Authorized the Repurchase of Up to $750M of the Company's Common Shrs >ALC.EB

25 feb 2025, 21:31 UTC

Ganancias

Alcon 4Q EPS 57c >ALC.EB

25 feb 2025, 21:31 UTC

Ganancias

Alcon 4Q Rev $2.5B >ALC.EB

17 dic 2024, 15:05 UTC

Charlas de Mercado

Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk

12 nov 2024, 17:38 UTC

Ganancias

Alcon Narrows 2024 View To Adj EPS $3.00-Adj EPS $3.05 >ALC

12 nov 2024, 17:38 UTC

Ganancias

Alcon Had Seen 2024 Sales $9.9B-$10.1B >ALC

12 nov 2024, 17:37 UTC

Ganancias

Alcon Cuts 2024 View To Sales $9.8B-$9.9B >ALC

12 nov 2024, 17:36 UTC

Ganancias

Alcon 3Q Core Operating Margin 20.6% >ALC

12 nov 2024, 17:36 UTC

Ganancias

Alcon 3Q Sales $2.43B >ALC

Comparación entre iguales

Cambio de precio

Alcon Inc previsión

Precio Objetivo

By TipRanks

15.91% repunte

Estimación a 12 Meses

Media 107.45 USD  15.91%

Máximo 120 USD

Mínimo 90 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alcon Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

18

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

90.87 / 92.61Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

180 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.